Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024901

PRESIDENT AND CEO sold 14,936 shares at an average $27.51 ($410,867)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kintz Samuel PRESIDENT AND CEO 2024-10-04 Sale 10b5-1 −12,206 $27.51 $335,792 1,036,523 I: show line 1 in the form
Kintz Samuel PRESIDENT AND CEO 2024-10-07 Sale 10b5-1 −2,730 $27.50 $75,075 1,033,793 I: show line 2 in the form
Open-market sales · 14,936 sh · avg $27.51 · $410,867
Loading xslF345X05/form4-10082024_101015.xml…